HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]

PhysioSonics (Seattle, WA) a development-stage device company focused on ultrasound imaging to monitor blood flow in the brain, closed a $3.6M Series B financing. Participants include Medtronic.

OrthoSensor (Sunrise, FL) a development-stage medical device company focused on remote monitoring of orthopedic implants, closed a $21M Series B financing. Participants include Ziegler Meditech Equity Partners.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.

Polyplus-Transfection (France) a commercial-stage nucleic acid reagent company, closed a $3.5M Series B financing. Participants include Alsace Inter Regio Fonds d’Investissement, Sudinnova, CIC Vizille Capital Innovation and CIC Finance.

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Dekkun (Cambridge, MA) a development-stage bioscience company focused on treatments of bone fractures and oncology. Participants include HealthCare Ventures.

Mithridion (Madison, WI) a clinical-stage biopharmaceutical company focused on CNS disorders with an initial focus on Alzheimer’s and schizophrenia, closed a $1.2M Series C financing. Participants include, Venture Investors, the State of Wisconsin Investment Board and Rocket Venture Fund.

Plasticell (United Kingdom) a development-stage biotechnology company focused on high throughput technologies for directed stem cell differentiation, closed a $5.6M Series A financing. Participants include Villay Asset Management.

Scil Proteins (Germany) a clinical-stage biopharmaceutical company focused on inflammation, infectious disease and oncology, closed a $33.8M Series B financing. Participants include BioNet Holding.

Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on hepatic disease and oncology, closed a $20M Series B financing. Participants include AgeChem Venture Fund, Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners and Roche Venture Fund.

Acetylon Pharmaceuticals (Cambridge, MA) a clinical-stage developer of selective deacetylase enzyme inhibitors focused on multiple myeloma, closed a $12.4M Series B financing. Participants include NewSpring Health Capital and others.

SymBio Pharmaceuticals (Japan) a commercial-stage pharmaceutical company focused on non-Hodgkin’s lymphoma, multiple myeloma and other hematological indications, closed a $24M Series E financing. Participants include Cephalon, Nippon Venture Capital, SMBC Venture Capital, MBL Venture Capital and JAFCO.